{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:54Z","timestamp":1792090014876,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Continuous and maintenance therapy remains central to multiple myeloma (MM) care, but repeated treatment-related healthcare encounters may impose physical, psychosocial, and logistical burden. We explored patient preferences regarding intervals between active treatment contacts, monitoring trade-offs, and opportunities to improve inpatient and outpatient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 12-month, single-center mixed-methods survey was conducted among 100 patients with MM at a German tertiary center. The survey assessed the perceived importance and preferred length of treatment-free intervals (TFIs), monitoring perceptions, relapse-risk trade-offs, inpatient stressors, and care-improvement proposals. Quantitative responses were summarized with item-specific denominators and exact 95% confidence intervals (CIs). Free-text responses underwent inductive content analysis by two independent raters and mixed-methods integration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Intervals between inpatient treatments were rated 10\/10 by 49\/100 participants (49.0%; 95% CI 38.9\u201359.2) and 0\/10 by 9\/100 (9.0%; 95% CI 4.2\u201316.4). The most frequently reported inpatient stressors were separation from family (27.0%), treatment-related symptoms or side effects (23.0%), and fatigue (17.0%). Regular check-ups were reassuring for 77\/100 (77.0%; 95% CI 67.5\u201384.8) and burdensome for 13\/100 (13.0%; 95% CI 7.1\u201321.2). Seven of 100 participants (7.0%; 95% CI 2.9\u201313.9) explicitly accepted higher relapse risk for longer TFIs. Preferred minimum interval length was heterogeneous; 39\/99 (39.4%; 95% CI 29.7\u201349.7) preferred\u2009&gt;\u20098\u00a0weeks. Qualitative narratives emphasized recovery, autonomy, restoration of routines, and modifiable care-process factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients frequently valued intervals between active treatment contacts for recovery, while monitoring was predominantly reassuring. These descriptive findings do not establish the safety or clinical appropriateness of longer TFIs but support prospective evaluation of preference-sensitive scheduling and monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-11255-z","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:29:54Z","timestamp":1790951394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient preferences for treatment\u2011free intervals in multiple myeloma: mixed\u2011methods insights on monitoring trade\u2011offs and supportive care improvements"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8760-3931","authenticated-orcid":false,"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie-Katrin","family":"Kadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"9","key":"11255_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA et al (2025) EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol 22(9):680\u2013700","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"11255_CR2","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1182\/hematology.2025000732","volume":"2025","author":"B Puliafito","year":"2025","unstructured":"Puliafito B, Cirstea D, Raje N (2025) Choosing the optimal maintenance strategy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2025(1):412\u2013423","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"29","key":"11255_CR3","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL et al (2017) Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol 35(29):3279\u20133289","journal-title":"J Clin Oncol"},{"issue":"1","key":"11255_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20(1):57\u201373","journal-title":"Lancet Oncol"},{"issue":"10","key":"11255_CR5","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1111\/imj.70148","volume":"55","author":"G McCaughan","year":"2025","unstructured":"McCaughan G et al (2025) Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Intern Med J 55(10):1741\u20131751","journal-title":"Intern Med J"},{"issue":"14","key":"11255_CR6","doi-asserted-by":"publisher","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","volume":"149","author":"A Fleischer","year":"2023","unstructured":"Fleischer A et al (2023) A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol 149(14):12897\u201312902","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"11255_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00432-023-05570-9","volume":"150","author":"A Greinacher","year":"2024","unstructured":"Greinacher A et al (2024) The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states. J Cancer Res Clin Oncol 150(2):55","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"11255_CR8","first-page":"479","volume":"32","author":"C Buck","year":"2024","unstructured":"Buck C et al (2024) The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study. Support Care Cancer 32(7):479","journal-title":"Support Care Cancer"},{"issue":"23","key":"11255_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71401","volume":"14","author":"A Fleischer","year":"2025","unstructured":"Fleischer A et al (2025) Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan. Cancer Med 14(23):e71401","journal-title":"Cancer Med"},{"issue":"7","key":"11255_CR10","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00520-026-10863-z","volume":"34","author":"A Fleischer","year":"2026","unstructured":"Fleischer A et al (2026) Supportive care for talquetamab-related dysgeusia in multiple myeloma: mixed-methods evidence, nutrition-focused flowchart, and digital companion concept. Support Care Cancer 34(7):668","journal-title":"Support Care Cancer"},{"issue":"5","key":"11255_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/ejh.14392","volume":"114","author":"A Perrot","year":"2025","unstructured":"Perrot A et al (2025) Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes. Eur J Haematol 114(5):883\u2013889","journal-title":"Eur J Haematol"},{"issue":"2","key":"11255_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s11523-024-01122-4","volume":"20","author":"S Mettias","year":"2025","unstructured":"Mettias S et al (2025) Multiple myeloma: improved outcomes resulting from a rapidly expanding number of therapeutic options. Target Oncol 20(2):247\u2013267","journal-title":"Target Oncol"},{"issue":"1","key":"11255_CR13","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2025.045","volume":"17","author":"M Puppi","year":"2025","unstructured":"Puppi M et al (2025) Bispecific antibodies and CAR T in multiple myeloma: appropriate selection of patients and sequencing. Mediterr J Hematol Infect Dis 17(1):e2025045","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"11255_CR14","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1186\/s12885-025-15083-y","volume":"25","author":"M Boccadoro","year":"2025","unstructured":"Boccadoro M et al (2025) Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework. BMC Cancer 25(1):1676","journal-title":"BMC Cancer"},{"issue":"25","key":"11255_CR15","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S et al (2025) Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol 43(25):2766\u20132771","journal-title":"J Clin Oncol"},{"issue":"8","key":"11255_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC et al (2021) Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"6","key":"11255_CR17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/ejh.70025","volume":"115","author":"HG Pleitez","year":"2025","unstructured":"Pleitez HG et al (2025) From trials to practice: a 2025 review of idecabtagene vicleucel and ciltacabtagene autoleucel efficacy across clinical studies and real-world evidence. Eur J Haematol 115(6):533\u2013546","journal-title":"Eur J Haematol"},{"issue":"12","key":"11255_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009174","volume":"12","author":"A Fleischer","year":"2024","unstructured":"Fleischer A et al (2024) Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. J Immunother Cancer 12(12):e009174","journal-title":"J Immunother Cancer"},{"issue":"24","key":"11255_CR19","doi-asserted-by":"publisher","first-page":"6380","DOI":"10.1182\/bloodadvances.2025017081","volume":"9","author":"ERA Pennings","year":"2025","unstructured":"Pennings ERA et al (2025) Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe. Blood Adv 9(24):6380\u20136393","journal-title":"Blood Adv"},{"issue":"1","key":"11255_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1182\/hematology.2024000534","volume":"2024","author":"MR Bishop","year":"2024","unstructured":"Bishop MR (2024) Late complications and long-term care of adult CAR T-cell patients. Hematology Am Soc Hematol Educ Program 2024(1):109\u2013115","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"11255_CR21","volume":"25","author":"H Khoudari","year":"2026","unstructured":"Khoudari H et al (2026) Delayed fatal neurotoxicity in post CAR-T cell therapy for multiple myeloma, a case report. Leuk Res Rep 25:100577","journal-title":"Leuk Res Rep"},{"issue":"1","key":"11255_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje N et al (2023) Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 13(1):116","journal-title":"Blood Cancer J"},{"issue":"18","key":"11255_CR23","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","volume":"9","author":"R Banerjee","year":"2025","unstructured":"Banerjee R et al (2025) Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Adv 9(18):4720\u20134726","journal-title":"Blood Adv"},{"key":"11255_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1721820","volume":"17","author":"N Marneni","year":"2026","unstructured":"Marneni N et al (2026) Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience. Front Immunol 17:1721820","journal-title":"Front Immunol"},{"issue":"12","key":"11255_CR25","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15(12):e538\u2013e548","journal-title":"Lancet Oncol"},{"issue":"5","key":"11255_CR26","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1016\/j.clml.2026.01.013","volume":"26","author":"KM Kort\u00fcm","year":"2026","unstructured":"Kort\u00fcm KM et al (2026) An observational retrospective analysis of treatment patterns and effectiveness of standard of care for multiple myeloma patients exposed to lenalidomide and a proteasome inhibitor: BasecaMMp study. Clin Lymphoma Myeloma Leuk 26(5):e603-e610.e2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"11255_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1200\/JCO-25-01713","volume":"44","author":"R Banerjee","year":"2026","unstructured":"Banerjee R et al (2026) Past, present, and future of dexamethasone in multiple myeloma and AL amyloidosis. J Clin Oncol 44(10):903\u2013913","journal-title":"J Clin Oncol"},{"key":"11255_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592487","volume":"10","author":"M Martino","year":"2020","unstructured":"Martino M et al (2020) Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art. Front Oncol 10:592487","journal-title":"Front Oncol"},{"issue":"5","key":"11255_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.3390\/cancers18050755","volume":"18","author":"T Gregory","year":"2026","unstructured":"Gregory T et al (2026) Outpatient versus inpatient administration of ciltacabtagene autoleucel in multiple myeloma: a systematic review of clinical, economic, and humanistic outcomes. Cancers (Basel) 18(5):755","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11255_CR30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/ejh.70176","volume":"117","author":"AG Ram\u00edrez-Alvarado","year":"2026","unstructured":"Ram\u00edrez-Alvarado AG et al (2026) Outpatient delivery of step-up doses to rapidly initiate monthly doses of bispecific antibodies in multiple myeloma. Eur J Haematol 117(1):200\u2013209","journal-title":"Eur J Haematol"},{"key":"11255_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1630146","volume":"15","author":"AL Garfall","year":"2025","unstructured":"Garfall AL et al (2025) A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma. Front Oncol 15:1630146","journal-title":"Front Oncol"},{"issue":"7","key":"11255_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132","volume":"8","author":"CLBM Korst","year":"2024","unstructured":"Korst CLBM et al (2024) Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing. HemaSphere 8(7):e132","journal-title":"HemaSphere"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11255-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11255-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11255-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:49:00Z","timestamp":1792086540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11255-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11255"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11255-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8366273\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee of W\u00fcrzburg (AZ 246\/22) and conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for study participation and publication of anonymized data.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All included patients gave their consent for publication of the collected data.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AF received honoraria from GSK, BMS and Janssen. KMK received honoraria from Abbvie, Beigene, BMS, GSK, Johnson & Johnson, Menarini, Novartis, Pfizer and Sanofi. SKK received honoraria from Janssen. J.M.W.\u00a0reports personal fees or consultancy for\u00a0Johnson & Johnson, Sanofi, Takeda, Pfizer, Oncopeptides, Menarini-Stemline, Skyline Dx, Abbvie, Amgen and GSK. C.R. received honoraria from Janssen and Takeda. The other authors report no conflict of interests.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1050"}}